Gland Pharma Ltd reports Q2 FY27 revenue of ₹1,833.6 crore, up 23% year-on-year
- Revenue rose 2% sequentially; PAT was ₹290.8 crore, up 58% year-on-year and down 8% sequentially.
- Operating EBITDA margin was 26%, versus 27% in Q1 FY27 and 21% in Q2 FY26.
- Adjusted EBITDA was ₹503 crore at a 27% margin, including a one-off GST-related provision adjustment.
